Genotypic Variability in the Antibiotic Resistance Genes blaNDM and blaKPC in Klebsiella pneumoniae Isolated from ICU Patients

Fatima Moeen Abbas

doi:10.51699/cajmns.v7i3.3389

Authors

Fatima Moeen Abbas University of Babylon, College of Science for women, Biology Department, Iraq

DOI:

https://doi.org/10.51699/cajmns.v7i3.3389

Keywords:

Klebsiella pneumoniae, carbapenem resistance, blaNDM, blaKPC, ICU infections, multiple drug resistance, gene expression, molecular epidemiology, PCR

Abstract

Background: Klebsiella pneumoniae is a leading cause of multidrug-resistant infections, particularly in intensive care settings1,2, and represents a major challenge in healthcare-associated infection (HAI) management due to its capacity to horizontally acquire carbapenem resistance genes. Many studies shed light on antibiotic resistance genes, particularly those of the blaNDM and blaKPC genes in Klebsiella pneumoniae. Objective: This study aimed to analyze the genetic variation of Klebsiella pneumoniae isolates using the blaNDM and blaKPC genes obtained from ICU patients in Babylon Governorate, Iraq. Methods: A total of 200 clinical samples were collected from intensive care unit (ICU) patients, and 95 isolates were confirmed as carbapenem resistant (CRKP). Results: PCR results revealed that blaNDM was present in 73.7% of the isolates and blaKPC in 61.1% and both genes were present in 45.3% of the isolates. Our sequencing analysis showed various mutations at positions 70 (A → T) and 150 (C→G) were strongly associated with higher levels of resistance. High levels of expression of these genes were correlated with increased carbapenem resistance based on qPCR analysis. Clinical data also indicated that patients whose isolates contained both genes had a 50% higher mortality rate and an 18-day median hospital stay. Conclusion: The otcomes of the present study indicate the necessity for stronger implementation of molecular surveillance programs and strict infection control measures, as well as the need for the development of new therapeutic strategies in order to reduce CRKP transmission originating from hospitalized patients and subsequently imported into the ICU.

References

R. Beyrouthy et al., “Genotypic and phenotypic characterization of carbapenemase-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 65, no. 2, Art. no. e01491-20, 2021.

K. Bush, “Past and present perspectives on β-lactamases,” Antimicrobial Agents and Chemotherapy, vol. 62, no. 10, Art. no. e01076-18, 2018.

K. Bush and P. A. Bradford, “β-Lactamase inhibitors,” Journal of Antimicrobial Chemotherapy, vol. 75, no. 5, pp. 1017–1042, 2020.

L. Chen et al., “Carbapenemase-producing Klebsiella pneumoniae: Molecular and genetic dissemination,” Journal of Clinical Microbiology, vol. 52, no. 2, pp. 438–448, 2014.

Y. Doi et al., “Carbapenemase-producing Enterobacteriaceae: Trends and treatment strategies,” Clinical Microbiology Reviews, vol. 30, no. 2, pp. 291–312, 2017.

L. Dortet et al., “Carbapenemase-producing Enterobacteriaceae: Evolution and management,” Antimicrobial Resistance and Infection Control, vol. 3, Art. no. 13, 2014.

C. L. Gorrie et al., “The global spread and clinical impact of carbapenem-resistant Klebsiella pneumoniae,” Clinical Infectious Diseases, vol. 68, no. 4, pp. 670–677, 2019.

T. Karampatakis et al., “Impact of carbapenem resistance in ICU Klebsiella pneumoniae infections,” Infection Control & Hospital Epidemiology, vol. 43, no. 3, pp. 310–316, 2022.

K. K. Kumarasamy et al., “Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: NDM-1,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 597–602, 2010.

L. K. Logan and R. A. Weinstein, “The epidemiology of carbapenem-resistant Enterobacteriaceae: A problem on the rise,” The Journal of Infectious Diseases, vol. 215, suppl. 1, pp. S28–S36, 2017.

R. Beyrouthy et al., “Genotypic and phenotypic characterization of carbapenemase-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 65, no. 2, Art. no. e01491-20, 2021.

L. Chen et al., “Carbapenemase-producing Klebsiella pneumoniae: Molecular and genetic dissemination,” Journal of Clinical Microbiology, vol. 52, no. 2, pp. 438–448, 2014.

Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed. Wayne, PA, USA: CLSI, 2023.

Y. Doi et al., “Carbapenemase-producing Enterobacteriaceae: Trends and treatment strategies,” Clinical Microbiology Reviews, vol. 30, no. 2, pp. 291–312, 2017.

C. L. Gorrie et al., “Genomic epidemiology of carbapenem-resistant Klebsiella pneumoniae,” Clinical Infectious Diseases, vol. 68, no. 4, pp. 670–677, 2019.

J. M. Janda and S. L. Abbott, “16S rRNA gene sequencing for bacterial identification in clinical microbiology,” Journal of Clinical Microbiology, vol. 45, no. 9, pp. 2761–2764, 2007.

K. K. Kumarasamy et al., “Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: NDM-1,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 597–602, 2010.

L. K. Logan and R. A. Weinstein, “The epidemiology of carbapenem-resistant Enterobacteriaceae: A problem on the rise,” The Journal of Infectious Diseases, vol. 215, suppl. 1, pp. S28–S36, 2017.

L. S. Munoz-Price et al., “Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases,” The Lancet Infectious Diseases, vol. 13, no. 9, pp. 785–796, 2013.

M. W. Pfaffl, “A new mathematical model for relative quantification in real-time RT-PCR,” Nucleic Acids Research, vol. 29, no. 9, Art. no. e45, 2001.

B. Albiger et al., “Carbapenemase-producing Enterobacteriaceae in Europe,” Eurosurveillance, vol. 20, no. 45, Art. no. 30062, 2015.

R. Beyrouthy et al., “Genotypic and phenotypic characterization of carbapenemase-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 65, no. 2, Art. no. e01491-20, 2021.

K. Bush and P. A. Bradford, “β-Lactamase inhibitors,” Journal of Antimicrobial Chemotherapy, vol. 75, no. 5, pp. 1017–1042, 2020.

L. Chen et al., “Carbapenemase-producing Klebsiella pneumoniae: Molecular and genetic dissemination,” Journal of Clinical Microbiology, vol. 52, no. 2, pp. 438–448, 2014.

Y. Doi et al., “Carbapenemase-producing Enterobacteriaceae: Trends and treatment strategies,” Clinical Microbiology Reviews, vol. 30, no. 2, pp. 291–312, 2017.

K. K. Kumarasamy et al., “Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: NDM-1,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 597–602, 2010.

L. K. Logan and R. A. Weinstein, “The epidemiology of carbapenem-resistant Enterobacteriaceae: A problem on the rise,” The Journal of Infectious Diseases, vol. 215, suppl. 1, pp. S28–S36, 2017.

L. S. Munoz-Price et al., “Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases,” The Lancet Infectious Diseases, vol. 13, no. 9, pp. 785–796, 2013.

J. D. Pitout et al., “Carbapenemase-producing Enterobacteriaceae: Global overview and challenges,” Infection and Drug Resistance, vol. 12, pp. 2593–2615, 2019.

K. L. Wyres and K. E. Holt, “Klebsiella pneumoniae as a key trafficker of drug resistance genes,” FEMS Microbiology Reviews, vol. 42, no. 3, pp. 415–438, 2018.